Introduction: Anemia is a common problem in HIV in sub-Saharan Africa. We describe the contribution of antiretroviral therapy (ART) regimen to the incidence of anemia and changes in hemoglobin (Hb) in HIV-infected patients in Uganda.
Methods: This study was nested in a prevention of cryptococcal disease trial (CRYPTOPRO; ISCRTN7648152). Patients received 3 different backbones of nucleoside reverse transcriptase inhibitor in a nonrandomized manner.
Results: Of the 852 patients (161 on zidovudine [ZDV], 628 on stavudine [d4T], and 63 on tenofovir [TDF]; all received lamuvidine), the risk of developing grade 4 anemia was higher (adjusted hazard ratio 2.7) for those receiving ZDV than those receiving d4T. Those receivingd4T had a higher average increase in Hb than those receiving ZDV (P = .024) or TDF (P = .014).
Conclusion: In this observational study, ZDV was associated with severe anemia compared to d4T or TDF; those receiving ZDV and TDF had smaller increases in Hb after ART initiation. We encourage publication of data on cohorts using TDF from Africa.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944840 | PMC |
| http://dx.doi.org/10.1177/2325957414557264 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL).
Leuk Res
January 2025
National Centre for Human Retrovirology and Department of Haematology, Imperial College Healthcare NHS Trust, UK; Department of Immunology & Inflammation, Imperial College London, UK. Electronic address:
Human T-cell leukaemia virus type-1 (HTLV-1) causes the highly aggressive malignancy adult T-cell leukaemia-lymphoma (ATL) in approximately 5 % of chronically infected carriers. HTLV-1 persists in the host by enhancing survival of infected-T-cells despite the presence of a strong immune response. Therefore, asymptomatic HTLV-1 carriers have a lifelong balance between infected cell proliferation and the host antiviral immune response.
View Article and Find Full Text PDFPregnancy Management in HIV Viral Controllers: Twenty Years of Experience.
Pathogens
April 2024
Department of Infectious Disease, Imperial College London, London W2 1PG, UK.
Article Synopsis
- The study looked at how women in the UK with HIV managed their pregnancies, especially those who can keep their virus levels very low without treatment.
- It compared pregnancies before and after 2012 when new guidelines changed how HIV was treated during pregnancy.
- Even with the changes in treatment, there were no new cases of HIV passed to babies, and the way babies were delivered varied quite a bit in recent years.
Comparison of safety and effectiveness of antiretroviral therapy regimens among pregnant women living with HIV at preconception or during pregnancy: a systematic review and network meta-analysis of randomized trials.
BMC Infect Dis
April 2024
HIV/STI Surveillance Research Center, WHO Collaborating Center for HIV, Surveillance Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Background: Mother-to-child transmission is the primary cause of HIV cases among children. Antiretroviral therapy (ART) plays a critical role in preventing mother-to-child transmission and reducing HIV progression, morbidity, and mortality among mothers. However, after more than two decades of ART during pregnancy, the comparative effectiveness and safety of ART medications during pregnancy are unclear, and existing evidence is contradictory.
View Article and Find Full Text PDFIntrapartum use of zidovudine in a large cohort of pregnant women living with HIV in Italy.
J Infect
November 2022
Paediatric Infectious Diseases Unit, Department of Health Sciences, Anna Meyer Children University Hospital, Florence, Italy.
Background: Intravenous administration of zidovudine (ZDV) during labour is a key step for vertical HIV transmission (VT) prevention, but there is no evidence of benefit when maternal HIV-RNA at delivery is <50 copies/mL. The aim of this study is evaluating the appropriateness of intrapartum ZDV use in Italy.
Methods: Observational study including mother-infant pairs with perinatal HIV exposure during 2002-2019, enrolled in the Italian Register for HIV Infection in Children.
Adverse perinatal outcomes associated with HAART and monotherapy.
AIDS
August 2022
National Perinatal Epidemiology Unit, Nuffield Department of Population Health.
Objectives: Assess adverse perinatal outcomes in pregnant women living with HIV (WLHIV) receiving HAART or zidovudine (ZDV) monotherapy, compared with antiretroviral therapy (ART)-naive WLHIV and HIV-negative women.
Design: Systematic review and meta-analysis.
Methods: We conducted a systematic literature review by searching PubMed, CINAHL, Global Health, and EMBASE for studies published between 1 January 1980 and 20 April 2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!